natgillin/translations-raw huggingface dataset:
In this study, the majority of patients (79%) mixed their short acting insulin with NPH insulin immediately prior to injection and 58% of subjects used oral hypoglycemic agents at randomization and were instructed to continue to use them at the same dose.
U ovom je ispitivanju većina bolesnika (79%) miješala kratkodjelujući inzulin s NPH inzulinom neposredno prije injiciranja, a 58% bolesnika je u trenutku randomizacije koristilo oralne hipoglikemike te su dobili uputu da ih nastave uzimati u istoj dozi.
In this study, the median TTP was 34.0 weeks (95% CI = 22.0 – 46.0 weeks).
U ovom je ispitivanju medijan vremena do tumorske progresije (engl. time to tumour progression, TTP) bio 34,0 tjedna (95% CI = 22,0–46,0 tjedana).
In this study, the multiple dose pharmacokinetic disposition of nevirapine and the five oxidative metabolites were not altered.
U ovoj studiji, izloženost farmakokinetici višestruke doze nevirapina i petoksidativnih metabolita nije se mijenjala.
In this study, the patients’ condition at the accident scene was compared with that at the end of the infusion of Cyanokit and over the following three days.
U ovom ispitivanju, stanje bolesnika na mjestu nesreće uspoređeno je s onim na kraju infuzije lijeka Cyanokit i tijekom tri naredna dana.
In this study, the primary measure of efficacy was the change from baseline in the total score of the Unified Parkinson’s Disease Rating Scale (UPDRS, parts I-III).
U ovom ispitivanju je primarna mjera djelotvornosti bila promjena od početne vrijednosti u ukupnom zbroju ujedinjene ljestvice za ocjenu Parkinsonove bolesti (engl.
In this study, two methods were used to classify renal function: the urinary creatinine clearance measured over 24 hours and the creatinine clearance estimated by Cockcroft-Gault formula.
U tom ispitivanju, funkcija bubrega klasificirana je na dva načina: prema klirensu kreatinina u mokraći mjerenom tijekom 24 sata, i klirensu kreatinina procijenjenom Cockcroft-Gaultovom formulom.
In this study, Tysabri is not compared with any other treatment.
U tom ispitivanju lijek Tysabri nije uspoređen ni s jednom drugom terapijom.
In this study, when used to treat bleeding, Voncento was rated excellent in 60.4% (396 out of 656) of the bleeding events and good in 36.0% (236 out of 656) of the bleeding events.
U tom ispitivanju, kada je korišten za liječenje krvarenja, lijek Voncento ocijenjen je odličnim u 60,4 % (396 od 656) epizoda krvarenje i dobrim u 36,0 % (236 od 656) epizoda krvarenja.
In this study, where patients were followed up for at least 6 months, around 32% (38 out of 120) of patients given Opdivo responded to treatment and had a reduction in their tumours compared with about 11% (5 out of 47) of patients given investigator’s choice of treatment (dacarbazine or a combination of carboplatin and paclitaxel).
U tom ispitivanju, u kojem se bolesnike pratilo barem 6 dodatnih mjeseci, oko 32 % (38 od 120) bolesnika koji su primili Opdivo pozitivno je reagiralo na liječenje te su im se smanjili tumori, u usporedbi s oko 11 % (5 od 47) bolesnika koji su liječeni terapijom po izboru ispitivača (dakarbazin ili kombinacija karboplatina i paklitaksela).
In this study, Xtandi was more effective than placebo at prolonging patients’ lives: on average, patients treated with Xtandi lived for 18.4 months, compared with 13.6 months for patients given placebo.
Tijekom tog ispitivanja lijek Xtandi bio je djelotvorniji od placeba u produljivanju životnoga vijeka bolesnika: bolesnici liječeni lijekom Xtandi prosječno su živjeli dulje, i to 18,4 mjeseca u usporedbi sa 13,6 mjeseci u bolesnika koji su primali placebo.
In this study, Zycortal was shown to be at least as effective as the other similar medicine.
U ovom ispitivanju, Zycortal se pokazao barem podjednako djelotvoran kao drugi slični VMP-ovi.
in this table for futher information regarding co- administration of REYATAZ with sildenafil.
u ovoj tablici za dodatne informacije o istovremenoj primjeni lijeka REYATAZ i sildenafila.
In this treatment subgroup comparison, XELOX plus bevacizumab was similar compared to FOLFOX-4 plus bevacizumab in terms of progression- free survival (hazard ratio 1.01; 97.5% CI 0.84 - 1.22).
Kod usporedbe tih liječenih podgrupa, XELOX protokol s bevacizumabom bio je sličan FOLFOX-4 protokolu s bevacizumabom u pogledu preživljenja bez progresije bolesti (omjer hazarda 1,01; 97,5% CI 0,84; 1,22).
In this trial no vaccine related SAEs were observed.
U ovom ispitivanju nisu zabilježeni ozbiljni neželjeni događaji povezani s cjepivom.
In this trial, 10 patients (homozygous for F508del-CFTR mutation) completed dosing with lumacaftor alone 400 mg q12h for 28 days followed by the addition of ivacaftor 250 mg q12h for an additional 28 days, and 25 patients (homozygous or heterozygous for F508del) completed dosing with placebo.
10 bolesnika (homozigoti za mutaciju F508del-CFTR) završilo je primjenu samo lumakaftora u dozi od 400 mg svakih 12 sati tijekom 28 dana, nakon čega je slijedio dodatak ivakaftora u dozi od 250 mg svakih 12 sati dodatnih 28 dana, a 25 bolesnika (homozigoti ili heterozigoti za F508del) završilo je s primjenom placeba.
In this trial, 160 patients were randomised to treatment with capecitabine (1000 mg/m2 twice daily for 2 weeks followed by a 7-day rest period) and cisplatin (80 mg/m2 as a 2-hour infusion every 3 weeks).
U tom je ispitivanju 160 bolesnika slučajnim odabirom liječeno kapecitabinom (1000 mg/m2 dvaput dnevno u trajanju od 2 tjedna, nakon čega slijedi pauza od 7 dana) i cisplatinom (80 mg/m2 u obliku dvosatne infuzije svaka tri tjedna).
In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3- week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m2 leucovorin IV followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).
U tom ispitivanju slučajnim odabirom 1987 bolesnika liječeno je kapecitabinom (1250 mg/m2 dvaput dnevno kroz 2 tjedna nakon čega slijedi jednotjedna pauza, ciklusi u 3-tjednim intervalima u razdoblju od 24 tjedna) ili 5-FU i leukovorinom (Mayo protokol: 20 mg/m2 leukovorina i.v. i 425 mg/m2 5-FU intravenski u bolusu od prvog do petog dana, svakih 28 dana u razdoblju od 24 tjedna).
In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3- week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).
U tom ispitivanju slučajnim odabirom 1987 bolesnika liječeno je kapecitabinom (1250 mg/m2 dvaput dnevno kroz 2 tjedna nakon čega slijedi jednotjedna pauza, ciklusi u 3-tjednim intervalima u razdoblju od 24 tjedna) ili 5-FU i leukovorinom (protokol Mayo klinike: 20 mg/m2 leukovorina i.v. i 425 mg/m2 5-FU i.v. u bolusu od prvog do petog dana, svakih 28 dana u razdoblju od 24 tjedna).
In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m2 leucovorin intravenous followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).
U tom ispitivanju slučajnim odabirom 1987 bolesnika liječeno je kapecitabinom (1250 mg/m2 dvaput dnevno kroz 2 tjedna nakon čega slijedi jednotjedna pauza, ciklusi u 3-tjednim intervalima u razdoblju od 24 tjedna) ili 5-FU i leukovorinom (protokol Mayo klinike: 20 mg/m2 leukovorina intravenski i 425 mg/m2 5-FU intravenski u bolusu od prvog do petog dana, svakih 28 dana u razdoblju od 24 tjedna).
In this trial, 255 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for weeks followed by 1-week rest period and docetaxel 75 mg/m2 as a 1 hour intravenous infusion every 3 weeks).
U tom je ispitivanju slučajnim odabirom 255 bolesnica liječeno kapecitabinom (1250 mg/m2 dvaput dnevno tijekom 2 tjedna, nakon čega je slijedila jednotjedna pauza i 75 mg/m2 docetaksela u jednosatnoj intravenskoj infuziji svaka 3 tjedna).
In this trial, 627 patients with metastatic colorectal carcinoma who have received prior treatment with irinotecan in combination with a fluoropyrimidine regimen as first line therapy were randomised to treatment with XELOX or FOLFOX-4.
U tom je ispitivanju 627 bolesnika s metastatskim kolorektalnim karcinomom, koji su liječeni irinotekanom u kombinaciji s fluoropirimidinom u prvoj liniji liječenja, randomizirano u skupine liječene XELOX protokolom ili FOLFOX-4 protokolom,.
In this trial, 627 patients with metastatic colorectal carcinoma who have received prior treatment with irinotecan in combination with a fluoropyrimidine regimen as first line therapy were randomised to treatment with XELOX or FOLFOX-4.
U tom je ispitivanju 627 bolesnika s metastatskim kolorektalnim karcinomom, koji su liječeni irinotekanom u kombinaciji s protokolom s fluoropirimidinom u prvoj liniji liječenja, randomizirano u skupine liječene XELOX protokolom ili FOLFOX-4 protokolom,.
In this trial, 944 patients were randomised to 3-week cycles for 24 weeks with capecitabine (1000 mg/m2 twice daily for 2 weeks followed by a 1-week rest period) in combination with oxaliplatin (130 mg/m2 intravenous infusion over 2-hours on day 1 every 3 weeks); 942 patients were randomised to bolus 5-FU and leucovorin.
3-tjednim ciklusima tijekom 24 tjedna (1000 mg/m2 dvaput dnevno u trajanju od 2 tjedna, nakon čega slijedi jednotjedna pauza) u kombinaciji s oksaliplatinom (130 mg/m2 u intravenskoj infuziji kroz 2 sata prvog dana ciklusa, svaka 3 tjedna); 942 bolesnika randomizirano je za liječenje bolusom 5-FU i leukovorinom.
In this trial, sixty six percent of the patients (686 out of 1,040) received at least one shortened infusion of 90 minutes or less and 44% of the patients (454 out of 1,040) received at least one shortened infusion of 60 minutes or less.
U ovom je ispitivanju 66% bolesnika (686 od 1040) primilo barem jednu infuziju u skraćenom trajanju od 90- minuta ili manje, a 44% bolesnika (454 od 1040) barem jednu infuziju u skraćenom trajanju od 60- minuta ili manje.
In this trial, the combination of ribavirin and peginterferon alfa-2b (1.5 micrograms/kg/week) was significantly more effective than the combination of ribavirin and interferon alfa-2b, particularly in patients infected with Genotype 1.
U ovom je ispitivanju kombinacija lijeka ribavirin i peginterferona alfa-2b (1,5 mikrograma/kg/tjedan) bila značajno djelotvornija od kombinacije lijeka ribavirin i interferona alfa-2b, osobito u bolesnika inficiranih genotipom 1.
In this trial, the combination of ribavirin and peginterferon alfa-2b (1.5 micrograms/kg/week) was significantly more effective than the combination of ribavirin and interferon alfa-2b, particularly in patients infected with Genotype 1.
U ovom je ispitivanju kombinacija ribavirina i peginterferona alfa-2b (1,5 mikrograma/kg/tjedan) bila značajno djelotvornija od kombinacije ribavirina i interferona alfa-2b, osobito u bolesnika inficiranih genotipom 1.
In this trial, the initial rechallenge administration was at a low dose and a lower infusion rate (1/2 the therapeutic dose at 1/25 the initial standard recommended rate).
U tom je ispitivanju ponovna primjena najprije uslijedila u maloj dozi i uz nižu brzinu infuzije (1/2 terapijske doze uz 1/25 početne standardne preporučene brzine).
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: < 20 kg, 20 - 40 kg, and > 40 kg.
U ovom su se ispitivanju udarna doza i doza održavanja leflunomida zasnivale na 3 kategorije tjelesne težine: < 20 kg, 20 - 40 kg i > 40 kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: < 20 kg, 20-40 kg, and > 40 kg.
U ovom su se ispitivanju udarna doza i doza održavanja leflunomida zasnivale na 3 kategorije tjelesne težine: <20 kg, 20-40 kg i >40 kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: <20 kg, 20-40 kg, and >40 kg.
U ovom su se ispitivanju udarna doza i doza održavanja leflunomida zasnivale na 3 kategorije tjelesne težine: < 20 kg, 20-40 kg i > 40 kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: <20 kg, 20-40 kg, and >40 kg.
U ovom su se ispitivanju udarna doza i doza održavanja leflunomida zasnivale na 3 kategorije tjelesne težine: <20 kg, 20-40 kg i >40 kg.
In this trial, the median levels of serum vitamin E, ALA, linoleic acid, EPA, DHA, and arachidonic acid decreased from baseline to Week 26 but remained above the lower limit of the reference range.
U ovom ispitivanju medijan serumskih vrijednosti vitamina E, alfa linolenske kiseline, linolne kiseline, eikosapentaenoične kiseline, dokosaheksaenoične kiseline i arahidonske kiseline je bio manji u odnosu na početne vrijednosti do 26. tjedna, ali je ostao iznad donje granice referentnog raspona.
In this type of surgery, Inductos can be used instead of an autogenous bone graft (bone taken from one part of a person’s body and placed in another part of the body).
U ovom tipu kirurškog zahvata, Inductos se može koristiti umjesto autogenog presatka kosti (kosti uzete iz jednog dijela tijela osobe i stavljene u drugi dio tijela).
In this user manual, the Dose Knob is shown in grey.
U ovom je priručniku gumb za doziranje prikazan sivom bojom.
In this way atazanavir reduces the risk of developing illnesses linked to HIV infection.
Na taj način atazanavir smanjuje rizik od razvoja bolesti povezanih s HIV infekcijom.
In this younger group of patients, adjunctive therapy with Diacomit should only be started when the diagnosis of SMEI has been clinically confirmed (see section 5.1).
Kod ove mlađe grupe bolesnika, dodatnu terapiju Diacomitom treba započeti isključivo ako je dijagnoza SMEI klinički potvrđena (vidjeti dio 5.1).
In those cases, sevelamer crystals appeared to have been associated with several non-listed gastrointestinal events such as colitis, ulcer, necrosis and peritonitis.
U tim se slučajevima činilo da su kristali sevelamera povezani s nekoliko nenavedenih gastrointestinalnih događaja kao što su kolitis, ulkus, nekroza i peritonitis.
In those clinical trials, undesirable effects reported with equal frequency in cancer patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation .
U tim kliničkim ispitivanjima, nuspojave zabilježene jednakom učestalošću u onkoloških bolesnika liječenih filgrastimom/kemoterapijom i placebom/kemoterapijom uključivale su mučninu i povraćanje, alopeciju, proljev, umor, anoreksiju (smanjen apetit), upalu sluznica, glavobolju, kašalj, osip, bol u prsištu, asteniju, faringolaringealni bol (orofaringealni bol) i konstipaciju.
In those clinical trials, undesirable effects reported with equal frequency in cancer patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation.
U tim kliničkim ispitivanjima, nuspojave zabilježene jednakom učestalošću u onkoloških bolesnika liječenih filgrastimom/kemoterapijom i placebom/kemoterapijom uključivale su mučninu i povraćanje, alopeciju, proljev, umor, anoreksiju (smanjen apetit), upalu sluznica, glavobolju, kašalj, osip, bol u prsištu, asteniju, faringolaringealni bol (orofaringealni bol) i konstipaciju.
In those clinical trials, undesirable effects reported with equal frequency in patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation.
U tim kliničkim ispitivanjima neželjeni učinci prijavljeni u bolesnika koji su primali kemoterapiju filgrastima, kao i u onih koji su primali placebo/kemoterapiju, ubrajaju se mučnina i povraćanje, alopecija, proljev, umor, anoreksija (smanjen apetit), upala sluznice, glavobolja, kašalj, osip, bol u prsištu, astenija, faringolaringealna bol (orolaringealna bol) i konstipacija.
In those clinical trials, undesirable effects reported with equal frequency in patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation.
U tim kliničkim ispitivanjima nuspojave prijavljene s jednakom učestalošću u bolesnika liječenih filgrastimom/kemoterapijom i bolesnika liječenih placebom/kemoterapijom uključivale su mučninu i povraćanje, alopeciju, proljev, umor, anoreksiju (smanjen apetit), upalu sluznice, glavobolju, kašalj, osip, bol u prsištu, asteniju, faringolaringealnu bol (bol u ustima i ždrijelu) i zatvor.
In those imiquimod patients who achieved total clearance of their warts, the median time to clearance was 12 weeks.
U bolesnika u kojih je zabilježen potpuni nestanak bradavica medijan razdoblja do izlječenja iznosio je 12 tjedana.
In those patients already taking an optimised dose of Spedra, alpha-blocker therapy should be initiated at the lowest dose.
U onih bolesnika koji već uzimaju optimiziranu dozu Spedre, terapiju alfa blokatorima treba započeti najnižom dozom.
In those patients already taking an optimized dose of vardenafil, alpha-blocker therapy should be initiated at the lowest dose.
U onih bolesnika koji već uzimaju sebi prilagođenu dozu vardenafila, terapiju alfa blokatorom treba započeti najnižom dozom.
In those patients in which diarrhoea led to discontinuation, it resolved after a few days of discontinuing treatment.
U bolesnika koji su prekinuli liječenje radi proljeva, nekoliko dana nakon prekida liječenja proljev je prestao.
In those patients where the same IV line is to be used to inject another medicinal product, the line must be adequately flushed prior to and after Dynastat injection with a solution of known compatibility.
U onih bolesnika u kojih se koristi ista i.v. linija za injiciranje drugog lijeka, linija se prije i nakon injiciranja Dynastata mora primjereno isprati otopinom za koju se zna da je kompatibilna.
In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with 0.9 % sodium chloride or 5 % glucose solution prior to and following the Rapilysin injection.
U bolesnika u kojih se mora koristiti isti intravenski put, taj se put (uključujući Y-nastavak) mora temeljito isprati 0,9%-tnom otopinom natrijevog klorida ili 5%-tnom otopinom glukoze prije i nakon ubrizgavanja lijeka Rapilysin.
In those patients who are stable on alpha-blocker therapy, avanafil should be initiated at the lowest dose of 50 mg.
U onih bolesnika koji su stabilni na terapiji alfa blokatorima, primjenu avanafila treba započeti najnižom dozom od 50 mg.
In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5 mg film-coated tablets.
U bolesnika stabilnih na terapiji alfa blokatorom, primjenu vardenafila treba započeti najmanjom preporučenom početnom dozom od 5 mg filmom obloženim tabletama.
In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5 mg.
U tih bolesnika koji su stabilni na terapiji alfa blokatorom vardenafil treba započeti najmanjom preporučenom početnom dozom od 5 mg.
In those patients who experience an infusion reaction, the method of infusion should be modified as follows:
U bolesnika s reakcijom na infuziju, istu je potrebno prilagoditi na sljedeći način:
In those patients who initially received infliximab and then switched to abatacept, the reduction in the mean DAS28 score from baseline were 3.29 at day 729 and 2.48 at day 365.
U bolesnika koji su u početku primali infliksimab, a potom su prebačeni na abatacept, smanjenje prosječnog DAS28 rezultata u odnosu na početne vrijednosti iznosilo je 3,29 729. dana te 2,48 365. dana.
In those who received the second vaccine 3 weeks to 5 years after vaccination with Pandemic influenza vaccine H5N1 MedImmune, antibodies increased 4-fold in 73% (8 out of 11) of the individuals compared with 10% of the individuals who had not been previously vaccinated with Pandemic influenza vaccine H5N1 MedImmune.
Kod onih koji su dobili drugo cjepivo 3 tjedna do 5 godina nakon cijepljenja cjepivom protiv pandemijske influence H5N1 MedImmune došlo je do četverostrukog povećanja antitijela u 73 % osoba (8 od 11) u odnosu na 10 % osoba koje nisu prethodno cijepljene cjepivom protiv pandemijske influence H5N1 MedImmune.
In three 12-month placebo-controlled trials of Zurampic in combination with a xanthine oxidase inhibitor versus a xanthine oxidase inhibitor alone (placebo), serum creatinine elevations between 1.5- fold and 2-fold over baseline occurred in 3.9% of patients on Zurampic 200 mg, 10.0% of patients on Zurampic 400 mg and 2.3% on placebo; serum creatinine elevations 2-fold or greater over baseline occurred in 1.8% of patients on Zurampic 200 mg, 6.7% of patients on Zurampic 400 mg and 0% on placebo.
U tri 12-mjesečna placebom kontrolirana ispitivanja lijeka Zurampic u kombinaciji s inhibitorom ksantin oksidaze u usporedbi sa samo inhibitorom ksantin oksidaze (uz placebo), razina serumskog kreatinina povisila se za 1,5 do 2 puta u odnosu na početnu vrijednost u 3,9% bolesnika liječenih lijekom Zurampic u dozi od 200 mg, 10% bolesnika liječenih lijekom Zurampic u dozi od 400 mg te 2,3% bolesnika liječenih placebom; do dvostrukog ili većeg povišenja razine serumskog kreatinina u odnosu na početnu vrijednost došlo je u 1,8% bolesnika u kojih je primjenjivan Zurampic u dozi od 200 mg, te 6,7% bolesnika u kojih je primjenjivan Zurampic u dozi od 400 mg i u 0% bolesnika koji su primali placebo.
In three comparative controlled trials, the immune response elicited by Rotarix liquid formulation was comparable to the one elicited by Rotarix lyophilised formulation.
U tri usporedna kontrolirana ispitivanja, imunološki je odgovor postignut tekućim oblikom cjepiva Rotarix bio usporediv s onim postignutim liofiliziranim oblikom cjepiva Rotarix.
In three comparative controlled trials, the immune response elicited by Rotarix liquid formulation was comparable to the one elicited by Rotarix lyophilised formulation.
U tri usporedna kontrolirana ispitivanja, imunološki je odgovor postignut tekućom formulacijom cjepiva Rotarix bio usporediv s onim postignutim liofiliziranom formulacijom cjepiva Rotarix.
In three main studies involving 3,292 women who needed to have ovarian stimulation, Elonva treatment was compared with treatment with follitropin beta (an FSH medicine also used to stimulate the ovaries).
U tri glavna ispitivanja koja su obuhvatila 3 292 žene kojima je bilo potrebno poticanje jajnika, liječenje lijekom Elonva uspoređeno je s liječenjem folitropinom beta (FSH lijekom koji se također koristio za poticanje jajnika).
In three of four patients the change in the sweat chloride test was <5 mmol/L and this group did not demonstrate a clinically relevant improvement in FEV1 after 8 weeks of treatment.
U tri od četiri bolesnika promjena rezultata testa koncentracije klorida u znoju iznosila je < 5 mmol/l i ta skupina nije pokazala klinički važno poboljšanje vrijednosti FEV1 nakon 8 tjedana liječenja.